Back to Journals » Drug Design, Development and Therapy » Volume 9

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

Total article views   HTML views PDF downloads Totals
24,917 Dovepress* 20,037+ 2,173 22,210
PubMed Central* 4,880 1,357 6,237
Totals 24,917 3,530 28,447
*Since 15 October 2015
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 1 0 0 1 2

View citations on PubMed Central and Google Scholar